The companies' first joint therapy will target a genetic disease marked by ammonia accumulating in the blood.
Illumina called the collaboration a “significant step” toward China Food and Drug Administration review and approval.
After dominating the research market, genomics giant Illumina set its sights on clinics.
NuVasive is poised to keep expanding into 2018, from its balance sheet to its headquarters.
Faheem Hasnain and Sheila Gujrathi — former executives of Receptos — have launched a new San Diego biopharmaceutical company...
LAW: Cos. Claim ACA Tax Damages Hiring and R&D
Carlsbad’s Ra Medical Systems is among the medtech companies that say the return of a 2.3 percent excise tax on medical devices sold in the U.S. threatens expansion and hiring plans.
Expansion Therapeutics was incubated within life science venture capital firm 5AM Ventures’ 4:59 Initiative.
The company’s new 50,000-square-foot facility on Barnes Canyon Road recently became fully operational.
Greenwich Biosciences developed epidolex, a treatment for seizures in two rare, severe childhood-onset epilepsy disorders.
Organovo designs and creates functional, three-dimensional human tissues for use in drug discovery, clinical development and therapeutic applications.
Tocagen brought on Martin “Marty” Duvall as CEO more than a year ago to commercialize its anti-cancer therapies. In 2017, the company marked several milestones on that front.
Robert Hemker, long an architect of Palomar Health District’s financial plans, retired in November.
Under the agreements, 3,000 employees received a retroactive pay raise.
The proceeds of this offering were initially earmarked for investigational new drug-enabling experiments.
The pharma giant is betting on Ignyta's cancer drug, entrectinib, which is intended to treat patients with rare cancers.